CLINICAL TRIAL: USE OF TH9507 IN HIV INFECTED INDIVIDUALS WITH EXCESS ABDOMINAL

临床试验：TH9507 在腹部过大的 HIV 感染者中的使用

• 批准号: 7731261
• 负责人: STEVEN K. GRINSPOON
• 金额: $ 1.34万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731261
• 关键词: Abdomen; Adipose tissue; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dyslipidemias; Fatty acid glycerol esters; Funding; Grant; HIV; Individual; Institution; Lipids; Lipodystrophy; Outcome; Research; Research Personnel; Resources; Somatotropin; Somatotropin-Releasing Hormone; Source; TH9507; United States National Institutes of Health; Visceral; Week

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV lipodystrophy is characterized by excess visceral fat, dyslipidemia, and low growth hormone (GH) levels. TH9507 is a GH releasing factor that physiologically increases GH levels. A previous study of TH9507 resulted in decreases in visceral adipose tissue (VAT) and trunk fat, increases in lean body mass and lipid profile improvement, and was generally well-tolerated. This study is aimed at investigating the effects of TH9507 for 26 weeks and duration of these benefits. The primary outcome is reduction of VAT.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 HIV脂肪营养不良的特征是过量内脏脂肪，血脂异常和低生长激素（GH）水平。 TH9507是生理上增加GH水平的GH释放因素。先前对TH9507的研究导致内脏脂肪组织（VAT）和树干脂肪的降低，体重增加和脂质谱的改善，并且通常耐受性良好。这项研究旨在研究26周的TH9507的影响以及这些好处的持续时间。主要结果是增值税的减少。